Sarepta Therapeutics (SRPT) is a publicly traded Healthcare sector company. As of May 21, 2026, SRPT trades at $17.55 with a market cap of $1.80B and a P/E ratio of 23.37. SRPT moved +2.88% today. Year to date, SRPT is -18.75%; over the trailing twelve months it is -57.19%. Its 52-week range spans $10.42 to $138.81. Analyst consensus is neutral with an average price target of $21.64. Rallies surfaces SRPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Recent SRPT insider activity includes Mayo Stephen sold 7.24K, Estepan Ian Michael sold 13.19K, and Nicaise Claude sold 2.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
| Metric | Value |
|---|---|
| Price | $17.55 |
| Market Cap | $1.80B |
| P/E Ratio | 23.37 |
| EPS | $0.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $138.81 |
| 52-Week Low | $10.42 |
| Volume | 1.65K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.18B |
| Net Income | $65.06M |
| Gross Margin | 0.00% |
24 analysts cover SRPT: 0 strong buy, 6 buy, 13 hold, 5 sell, 0 strong sell. Consensus rating is neutral. Average price target: $21.64.